121 related articles for article (PubMed ID: 28648122)
1. Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6.
Chen X; Jiang J; Giri N; Hu P
Xenobiotica; 2018 May; 48(5):459-466. PubMed ID: 28648122
[TBL] [Abstract][Full Text] [Related]
2. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
[TBL] [Abstract][Full Text] [Related]
3. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers.
Bello CL; LaBadie RR; Ni G; Boutros T; McCormick C; Ndongo MN
Cancer Chemother Pharmacol; 2012 Apr; 69(4):991-7. PubMed ID: 22147075
[TBL] [Abstract][Full Text] [Related]
4. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib.
Piscitelli J; Chen J; LaBadie RR; Salageanu J; Chung CH; Tan W
Clin Drug Investig; 2022 Mar; 42(3):221-235. PubMed ID: 35195881
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib.
Giri N; Masters JC; Plotka A; Liang Y; Boutros T; Pardo P; O'Connell J; Bello C
Invest New Drugs; 2015 Aug; 33(4):931-41. PubMed ID: 26048096
[TBL] [Abstract][Full Text] [Related]
7. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers.
Marasanapalle VP; Masimirembwa C; Sivasubramanian R; Sayyed S; Weinzierl-Hinum A; Mehta D; Kapungu NN; Kanji C; Thelingwani R; Zack J
J Clin Pharmacol; 2024 May; 64(5):578-589. PubMed ID: 37803948
[TBL] [Abstract][Full Text] [Related]
9. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP2D6*5 and *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects.
Guo L; Wang S; Wan Z; Ni S; Xu B; Zhao X; Liu L
J Clin Pharm Ther; 2020 Aug; 45(4):632-637. PubMed ID: 32379356
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems.
Chen R; Wang H; Shi J; Shen K; Hu P
Eur J Clin Pharmacol; 2015 Jul; 71(7):835-41. PubMed ID: 25967538
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT).
Chiu JW; Chan K; Chen EX; Siu LL; Abdul Razak AR
Invest New Drugs; 2015 Aug; 33(4):895-900. PubMed ID: 25937431
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
Bramer SL; Suri A
Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
[TBL] [Abstract][Full Text] [Related]
14. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.
Ruiz-Garcia A; Masters JC; Mendes da Costa L; LaBadie RR; Liang Y; Ni G; Ellery CA; Boutros T; Goldberg Z; Bello CL
J Clin Pharmacol; 2016 Feb; 56(2):223-30. PubMed ID: 26179237
[TBL] [Abstract][Full Text] [Related]
15. Effects of CYP2D6 *10 and *41 Variants in Healthy Chinese Men on the Pharmacokinetics of Dapoxetine.
Wang Z; Gao Y; Ji X; Wu T; Pu L; Qiu W
J Clin Pharmacol; 2024 May; 64(5):601-608. PubMed ID: 38059315
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.
Jin SK; Chung HJ; Chung MW; Kim JI; Kang JH; Woo SW; Bang S; Lee SH; Lee HJ; Roh J
J Clin Pharm Ther; 2008 Oct; 33(5):567-73. PubMed ID: 18834373
[TBL] [Abstract][Full Text] [Related]
17. Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
Kim DW; Garon EB; Jatoi A; Keefe DM; Lacouture ME; Sonis S; Gernhardt D; Wang T; Giri N; Doherty JP; Nadanaciva S; O'Connell J; Sbar E; Cho BC
Lung Cancer; 2017 Apr; 106():76-82. PubMed ID: 28285698
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
[TBL] [Abstract][Full Text] [Related]
19. Possible interethnic differences in omeprazole pharmacokinetics : comparison of Jordanian Arabs with other populations.
Shilbayeh S; Tutunji MF
Clin Pharmacokinet; 2006; 45(6):593-610. PubMed ID: 16719541
[TBL] [Abstract][Full Text] [Related]
20. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]